A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)
Who can take part
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
You may be able to take part in this trial if you:
- are aged 18 years or older
- have a diagnosis of low grade serous ovarian cancer
- gave progression or recurrence of low grade serous ovarian cancer after receiving at least one type of platinum based (carboplatin or cisplatin) chemotherapy
- have disease on imaging that can be measured
- are In good general physical health
This is not an exhaustive list. If you're interested in participating in a clinical trial, you should speak to your doctor about what other criteria might apply.
About the trial
This trial is for those with a diagnosis of low grade serous ovarian cancer that has come back after having had at least one type of platinum chemotherapy. It is an open label study, which means that both you and your doctor will know which treatment you are receiving.
The researchers conducting the trial are testing the combination of two drugs called Avutometinib and Defactinib. They will compare these two drugs with different types of chemotherapy or hormonal treatments that are the current standard treatment for recurrent low grade serous ovarian cancer.
Avutometinib and Defactinib are both a type of drug called a kinase inhibitor. Kinase inhibitors block cancer cell growth. The purpose of the study is to find out how safe it is to use the combination of Avutometinib and Defactinib and whether these drugs are more effective than the standard treatment options.
The drugs being tested in in this trial are:
- Avutometinib – a kinase inhibitor (a tablet taken by mouth)
- Defactinib – a kinase inhibitor (a tablet taken by mouth)
Ramp 301 has 2 different treatment arms and if you take part, you will be randomised (placed into a treatment group by a computer) into one of the treatment groups:
- Avutometinib and Defactinib
- Standard treatment options selected by the doctor:
- Pegylated liposomal doxorubicin (Caelyx) – a chemotherapy drug (given via a drip into the vein)
- Paclitaxel – a chemotherapy drug (given via a drip into the vein)
- Topotecan – a chemotherapy drug (given via a drip into the vein)
- Letrozole – an aromatase inhibitor (a tablet taken by mouth)
- Anastrozole – an aromatase inhibitor (a tablet taken by mouth)
If you are assigned to one of the standard treatments and your cancer gets worse during treatment the research team can decide to change your treatment to the combination of Avutometinib plus Defactinib.
All participants will be followed up by the research team.
This information was last reviewed on 10/02/2025. Please note that the status of clinical trials can change at short notice. You should always check with your clinical team which trials may be suitable for your situation.
